ImmPACT Bio is a biotechnology startup committed to harnessing the power of engineered T-cells to target solid tumors while preserving healthy tissues. Founded in 2017, the company focuses on developing precise engineered T-cells for treating solid tumors. Their innovative technology targets the loss-of-gene attributes in solid tumor cells, while preserving the integrity of normal, healthy tissues.
The startup recently received a significant $8.00M grant investment on 28 February 2024 from the California Institute for Regenerative Medicine.
With its pioneering approach in the biotechnology industry, ImmPACT Bio is poised to make a substantial impact in the field of cancer treatment through its groundbreaking technology.
